U.S. markets close in 5 hours 19 minutes
  • S&P 500

    4,244.08
    -2.51 (-0.06%)
     
  • Dow 30

    34,255.96
    -43.37 (-0.13%)
     
  • Nasdaq

    14,097.90
    +25.04 (+0.18%)
     
  • Russell 2000

    2,308.54
    -11.53 (-0.50%)
     
  • Crude Oil

    72.26
    +0.14 (+0.19%)
     
  • Gold

    1,860.40
    +4.00 (+0.22%)
     
  • Silver

    27.92
    +0.23 (+0.82%)
     
  • EUR/USD

    1.2130
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4910
    -0.0080 (-0.53%)
     
  • GBP/USD

    1.4108
    +0.0026 (+0.18%)
     
  • USD/JPY

    109.9640
    -0.0700 (-0.06%)
     
  • BTC-USD

    39,252.24
    -716.18 (-1.79%)
     
  • CMC Crypto 200

    973.16
    -19.31 (-1.95%)
     
  • FTSE 100

    7,182.91
    +10.43 (+0.15%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

Monthly information on share capital and company voting rights

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date

Total number of shares
in the capital

Total number of voting rights

04/30/2021

45,461,310

51,526,159


About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN® is a registered trademark owned by Cellectis.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Communications Manager, +33776991433, media@cellectis.com

IR contact:
Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

Attachment